The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Relationship between Tumor Enhancement, Edema,IDH1 Mutational Status,MGMT Promoter Methylation, and Survival in Glioblastoma
Open accessAbstract
BACKGROUND AND PURPOSE: Both IDH1 mutation and MGMT promoter methylation are associated with longer survival. We investigated the ability of imaging correlates to serve as noninvasive biomarkers for these molecularly defined GBM subtypes. MATERIALS AND METHODS: MR imaging from 202 patients with GBM was retrospectively assessed for nonenhancing tumor and edema among other imaging features. IDH1 mutational and MGMT promoter methylation status were determined by DNA sequencing and methylation-specific PCR, respectively. Overall survival was determined by using a multivariate Cox model and the Kaplan-Meier method with a log rank test. A logistic regression model followed by ROC analysis was used to classify the IDH1 mutation and methylation status by using imaging features. RESULTS: MGMT promoter methylation and IDH1 mutation were associated with longer median survival. Edema levels stratified survival for methylated but not unmethylated tumors. Median survival for methylated tumors with little/no edema was 2476 days (95% CI, 795), compared with 586 days (95% CI, 507-654) for unmethylated tumors or tumors with edema. All IDH1 mutant tumors were nCET positive, and most (11/14, 79%) were located in the frontal lobe. Imaging features including larger tumor size and nCET could be used to determine IDH1 mutational status with 97.5% accuracy, but poorly predicted MGMT promoter methylation. CONCLUSIONS: Imaging features are potentially predictive of IDH1 mutational status but were poorly correlated with MGMT promoter methylation. Edema stratifies survival in MGMT promoter methylated but not in unmethylated tumors; patients with methylated tumors with little or no edema have particularly long survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“Second, the IDH1 mutation is relatively rare in GBM because it is associated with secondary but not primary tumors.(7) We found that only 6.”
BackgroundPhillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Self-citationLacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E., et al. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,091
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Self-citationGlioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
Hegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 783
FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
Cohen, M. H., Shen, Y. L., Keegan, P., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0121 · Cited by 655
Weller, M., Felsberg, J., Hartmann, C., Berger, H., Steinbach, J. P., Schramm, J., Westphal, M., Schackert, G., Simon, M., Tonn, J. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0805 · Cited by 614
Lai, A., Tran, A., Nghiemphu, P. L., Pope, W. B., Solis, O. E., Selch, M., Filka, E., Yong, W. H., Mischel, P. S., Liau, L. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2729 · Cited by 458
Self-citation
Cited by
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Ellingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0507-6 · Cited by 476
Self-citationDeep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas
Chang, P., Grinband, J., Weinberg, B. D., Bardis, M., Khy, M., Cadena, G., Su, M.-Y., Cha, S., Filippi, C. G., Bota, D., et al. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5667 · Cited by 472
Patel, S. H., Poisson, L. M., Brat, D. J., Zhou, Y., Cooper, L., Snuderl, M., Thomas, C., Franceschi, A. M., Griffith, B., Flanders, A. E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0560 · Cited by 424
Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas
Zhang, B., Chang, K., Ramkissoon, S., Tanguturi, S., Bi, W. L., Reardon, D. A., Ligon, K. L., Alexander, B. M., Wen, P. Y., & Huang, R. Y. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now121 · Cited by 263
Prasanna, P., Patel, J., Partovi, S., Madabhushi, A., & Tiwari, P. (2017) · European Radiology · doi:10.1007/s00330-016-4637-3 · Cited by 261
Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma
Beig, N., Patel, J., Prasanna, P., Hill, V., Gupta, A., Correa, R., Bera, K., Singh, S., Partovi, S., Varadan, V., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18310-0 · Cited by 157
Ellingson, B. M. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0506-0 · Cited by 132
Self-citationRole of imaging in the era of precision medicine
Giardino, A., Gupta, S., Olson, E., Sepulveda, K., Lenchik, L., Ivanidze, J., Rakow-Penner, R., Patel, M. J., Subramaniam, R. M., & Ganeshan, D. (2017) · Academic Radiology · doi:10.1016/j.acra.2016.11.021 · Cited by 87
Jansen, R. W., van Amstel, P., Martens, R. M., Kooi, I. E., Wesseling, P., de Langen, A. J., Menke-Van der Houven van Oordt, C. W., Jansen, B. H. E., Moll, A. C., Dorsman, J. C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24893 · Cited by 63
Suchorska, B., Schüller, U., Biczok, A., Lenski, M., Albert, N. L., Giese, A., Kreth, F.-W., Ertl-Wagner, B., Tonn, J.-C., & Ingrisch, M. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.019 · Cited by 59
Metadata
- Authors
- Carrillo, J. A., Lai, A., Nghiemphu, P. L., Kim, H. J., Phillips, H. S., Kharbanda, S., Moftakhar, P., Lalaezari, S., Yong, W., Ellingson, B. M., Cloughesy, T. F., & Pope, W. B.
- Venue
- American Journal of Neuroradiology
- Published
- 2012-02-09
- Volume
- 33
- Issue
- 7
- Pages
- 1349-1355
- ISSN
- 0195-6108 (ISSN-L)
- 1936-959X
- OpenAlex
- W2165274879
- Cited by
- 299
- References
- 43
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.